Miller Edgar R, Pastor-Barriuso Roberto, Dalal Darshan, Riemersma Rudolph A, Appel Lawrence J, Guallar Eliseo
The Johns Hopkins School of Medicine, and The Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2223, USA.
Ann Intern Med. 2005 Jan 4;142(1):37-46. doi: 10.7326/0003-4819-142-1-200501040-00110. Epub 2004 Nov 10.
Experimental models and observational studies suggest that vitamin E supplementation may prevent cardiovascular disease and cancer. However, several trials of high-dosage vitamin E supplementation showed non-statistically significant increases in total mortality.
To perform a meta-analysis of the dose-response relationship between vitamin E supplementation and total mortality by using data from randomized, controlled trials.
135,967 participants in 19 clinical trials. Of these trials, 9 tested vitamin E alone and 10 tested vitamin E combined with other vitamins or minerals. The dosages of vitamin E ranged from 16.5 to 2000 IU/d (median, 400 IU/d).
PubMed search from 1966 through August 2004, complemented by a search of the Cochrane Clinical Trials Database and review of citations of published reviews and meta-analyses. No language restrictions were applied.
3 investigators independently abstracted study reports. The investigators of the original publications were contacted if required information was not available.
9 of 11 trials testing high-dosage vitamin E (> or =400 IU/d) showed increased risk (risk difference > 0) for all-cause mortality in comparisons of vitamin E versus control. The pooled all-cause mortality risk difference in high-dosage vitamin E trials was 39 per 10,000 persons (95% CI, 3 to 74 per 10,000 persons; P = 0.035). For low-dosage vitamin E trials, the risk difference was -16 per 10,000 persons (CI, -41 to 10 per 10,000 persons; P > 0.2). A dose-response analysis showed a statistically significant relationship between vitamin E dosage and all-cause mortality, with increased risk of dosages greater than 150 IU/d.
High-dosage (> or =400 IU/d) trials were often small and were performed in patients with chronic diseases. The generalizability of the findings to healthy adults is uncertain. Precise estimation of the threshold at which risk increases is difficult.
High-dosage (> or =400 IU/d) vitamin E supplements may increase all-cause mortality and should be avoided.
实验模型和观察性研究表明,补充维生素E可能预防心血管疾病和癌症。然而,几项高剂量补充维生素E的试验显示,总死亡率虽有增加,但无统计学意义。
通过使用随机对照试验的数据,对补充维生素E与总死亡率之间的剂量反应关系进行荟萃分析。
19项临床试验中的135967名参与者。在这些试验中,9项单独测试维生素E,10项测试维生素E与其他维生素或矿物质的组合。维生素E的剂量范围为16.5至2000国际单位/天(中位数为400国际单位/天)。
1966年至2004年8月的PubMed搜索,并辅以对Cochrane临床试验数据库的搜索以及对已发表综述和荟萃分析的参考文献的审查。未设语言限制。
3名研究人员独立提取研究报告。如果没有所需信息,则联系原始出版物的研究人员。
11项测试高剂量维生素E(≥400国际单位/天)的试验中有9项显示,在维生素E与对照组的比较中,全因死亡率风险增加(风险差异>0)。高剂量维生素E试验中汇总的全因死亡率风险差异为每10000人39例(95%置信区间为每10000人3至74例;P = 0.035)。对于低剂量维生素E试验,风险差异为每10000人-16例(置信区间为每10000人-41至10例;P>0.2)。剂量反应分析显示,维生素E剂量与全因死亡率之间存在统计学上的显著关系,剂量大于150国际单位/天时风险增加。
高剂量(≥400国际单位/天)试验通常规模较小,且在患有慢性病的患者中进行。这些结果对健康成年人的普遍性尚不确定。难以精确估计风险增加的阈值。
高剂量(≥400国际单位/天)的维生素E补充剂可能会增加全因死亡率,应避免使用。